Horne Joanne, Carr Norman J, Bateman Adrian C, Kandala Ngianga, Adams Jody, Silva Sónia, Ryder Isobel
Cellular Pathology Department, University Hospital Southampton NHS Foundation Trust Southampton General Hospital, Southampton, Hampshire, UK.
School of Health Sciences and Social Work, University of Portsmouth, Portsmouth, UK.
J Clin Pathol. 2016 Jun;69(6):511-7. doi: 10.1136/jclinpath-2015-203281. Epub 2015 Nov 30.
The Royal College of Pathologists recommend that a median of at least 12 lymph nodes should be harvested during pathological staging of colorectal cancer. It is not always easy to harvest the required number, especially in patients with rectal cancer receiving neoadjuvant therapy. Lymph node revealing solutions, for example, GEWF, may improve nodal yield. GEWF is safe, cheap and easy to use.
In a controlled trial, lymph node yields were compared after secondary specimen dissection following either 24 h of further fixation in formalin (n=101) or GEWF immersion (n=99). The number, size and tumour status of additional lymph nodes identified were compared between groups. Twenty-seven cases that received long-course neoadjuvant therapy were also assessed.
Median lymph node yield at primary dissection met national standards overall (19) but also in the long-course neoadjuvant therapy group (13). Lymph nodes were smaller in neoadjuvant cases compared with non-neoadjuvant cases (mean size range 1.3-5.6 mm vs 1.5-8.9 mm). The use of further fixation and GEWF detected more nodes at secondary dissection. The mean number of additional nodes harvested was greater with formalin (8.3) than GEWF (7.3). There was no significant difference in the mean size of the additional lymph nodes detected between groups (point estimate 1.02; 95% CI -0.58 to 2.63; p=0.211). Upstaging triggering adjunct chemotherapy occurred in 1% (2/200) of cases.
The routine use of adjunct techniques to identify additional lymph nodes is unnecessary with underlying high-quality dissection practice. Emphasis should be placed upon education and training, spending appropriate time dissecting and ensuring specimens are sufficiently fixed beforehand.
皇家病理学家学院建议,在结直肠癌病理分期过程中,平均至少应采集12个淋巴结。采集所需数量的淋巴结并非总是容易的,尤其是在接受新辅助治疗的直肠癌患者中。淋巴结显影剂,例如GEWF,可能会提高淋巴结的获取量。GEWF安全、便宜且易于使用。
在一项对照试验中,比较了在福尔马林中进一步固定24小时(n = 101)或GEWF浸泡(n = 99)后二次标本解剖后的淋巴结获取量。比较了两组之间识别出的额外淋巴结的数量、大小和肿瘤状态。还评估了27例接受长疗程新辅助治疗的病例。
初次解剖时的中位淋巴结获取量总体上符合国家标准(19个),长疗程新辅助治疗组也是如此(13个)。与非新辅助治疗病例相比,新辅助治疗病例中的淋巴结较小(平均大小范围为1.3 - 5.6毫米对1.5 - 8.9毫米)。进一步固定和GEWF的使用在二次解剖时检测到更多淋巴结。福尔马林组采集的额外淋巴结平均数量(8.3个)多于GEWF组(7.3个)。两组之间检测到的额外淋巴结的平均大小没有显著差异(点估计值1.02;95%置信区间 -0.58至2.63;p = 0.211)。1%(2/200)的病例出现了因分期上调而触发辅助化疗的情况。
在具备高质量解剖实践的情况下,无需常规使用辅助技术来识别额外的淋巴结。应强调教育和培训,花费适当时间进行解剖,并确保标本预先充分固定。